Search Results - "Cabanillas, E."

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond by Cabanillas, Maria E, Ryder, Mabel, Jimenez, Camilo

“…The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade, with multiple kinase inhibitor drug approvals for each subtype of…”
Get full text

Thyroid cancer by Cabanillas, Maria E, Dr, McFadden, David G, MD, Durante, Cosimo, MD

“…Summary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The…”
Get full text

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers by Wirth, Lori J, Sherman, Eric, Robinson, Bruce, Solomon, Benjamin, Kang, Hyunseok, Lorch, Jochen, Worden, Francis, Brose, Marcia, Patel, Jyoti, Leboulleux, Sophie, Godbert, Yann, Barlesi, Fabrice, Morris, John C, Owonikoko, Taofeek K, Tan, Daniel S.W, Gautschi, Oliver, Weiss, Jared, de la Fouchardière, Christelle, Burkard, Mark E, Laskin, Janessa, Taylor, Matthew H, Kroiss, Matthias, Medioni, Jacques, Goldman, Jonathan W, Bauer, Todd M, Levy, Benjamin, Zhu, Viola W, Lakhani, Nehal, Moreno, Victor, Ebata, Kevin, Nguyen, Michele, Heirich, Dana, Zhu, Edward Y, Huang, Xin, Yang, Luxi, Kherani, Jennifer, Rothenberg, S. Michael, Drilon, Alexander, Subbiah, Vivek, Shah, Manisha H, Cabanillas, Maria E

“…Medullary thyroid cancer often develops in patients with somatic or germline mutations in RET . Selpercatinib is a novel RET inhibitor. In a phase 1–2 trial, a…”
Get full text

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer by Fullmer, Tanner, Cabanillas, Maria E, Zafereo, Mark

“…Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until recently, there were limited therapeutic options. However, over…”
Get full text

Vemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial by Brose, Marcia S, Dr, Cabanillas, Maria E, MD, Cohen, Ezra E W, Prof, Wirth, Lori J, MD, Riehl, Todd, PharmD, Yue, Huibin, PhD, Sherman, Steven I, Prof, Sherman, Eric J, MD

“…Summary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase…”
Get full text

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer by Schlumberger, Martin, Jarzab, Barbara, Cabanillas, Maria E, Robinson, Bruce, Pacini, Furio, Ball, Douglas W, McCaffrey, Judith, Newbold, Kate, Allison, Roger, Martins, Renato G, Licitra, Lisa F, Shah, Manisha H, Bodenner, Donald, Elisei, Rossella, Burmeister, Lynn, Funahashi, Yasuhiro, Ren, Min, O'Brien, James P, Sherman, Steven I

“…Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid…”
Get full text

Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics by Lu, Lina, Wang, Jennifer Rui, Henderson, Ying C, Bai, Shanshan, Yang, Jie, Hu, Min, Shiau, Cheng-Kai, Pan, Timothy, Yan, Yuanqing, Tran, Tuan M, Li, Jianzhuo, Kieser, Rachel, Zhao, Xiao, Wang, Jiping, Nurieva, Roza, Williams, Michelle D, Cabanillas, Maria E, Dadu, Ramona, Busaidy, Naifa Lamki, Zafereo, Mark, Navin, Nicholas, Lai, Stephen Y, Gao, Ruli

“…The deadliest anaplastic thyroid cancer (ATC) often transforms from indolent differentiated thyroid cancer (DTC); however, the complex intratumor…”
Get full text

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment by Cabanillas, Maria E., Schlumberger, Martin, Jarzab, Barbara, Martins, Renato G., Pacini, Furio, Robinson, Bruce, McCaffrey, Judith C., Shah, Manisha H., Bodenner, Donald L., Topliss, Duncan, Andresen, Corina, O'Brien, James P., Ren, Min, Funahashi, Yasuhiro, Allison, Roger, Elisei, Rossella, Newbold, Kate, Licitra, Lisa F., Sherman, Steven I., Ball, Douglas W.

“…BACKGROUND Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1‐VEGFR3),…”
Get full text

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma by Iyer, Priyanka C, Dadu, Ramona, Gule-Monroe, Maria, Busaidy, Naifa L, Ferrarotto, Renata, Habra, Mouhammed Amir, Zafereo, Mark, Williams, Michelle D, Gunn, G Brandon, Grosu, Horiana, Skinner, Heath D, Sturgis, Erich M, Gross, Neil, Cabanillas, Maria E

“…Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the…”
Get full text

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance by Hamidi, Sarah, Hofmann, Marie-Claude, Iyer, Priyanka C, Cabanillas, Maria E, Hu, Mimi I, Busaidy, Naifa L, Dadu, Ramona

“…The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a…”
Get full text

Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns by Nguyen, Ha, Shah, Komal, Waguespack, Steven G, Hu, Mimi I, Habra, Mouhammed Amir, Cabanillas, Maria E, Busaidy, Naifa L, Bassett, Roland, Zhou, Shouhao, Iyer, Priyanka C, Simmons, Garrett, Kaya, Diana, Pitteloud, Marie, Subudhi, Sumit K, Diab, Adi, Dadu, Ramona

“…Data on the diagnosis, natural course and management of immune checkpoint inhibitor (ICI)-related hypophysitis (irH) are limited. We propose this study to…”
Get full text

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease by Busaidy, Naifa Lamki, Cabanillas, Maria E.

“…Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients that recur often require…”
Get full text

The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells by Puli, Oorvashi Roy, Danysh, Brian P, McBeath, Elena, Sinha, Deepankar K, Hoang, Nguyet M, Powell, Reid T, Danysh, Heather E, Cabanillas, Maria E, Cote, Gilbert J, Hofmann, Marie-Claude

“…The ETS family of transcription factors is involved in several normal remodeling events and pathological processes including tumor progression. ETS…”
Get full text

Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy by Turner, Naimah, Hamidi, Sarah, Ouni, Rim, Rico, Rene, Henderson, Ying C, Puche, Maria, Alekseev, Sayan, Colunga-Minutti, Jocelynn G, Zafereo, Mark E, Lai, Stephen Y, Kim, Sang T, Cabanillas, Maria E, Nurieva, Roza

“…Although most follicular-derived thyroid cancers are well differentiated and have an overall excellent prognosis following treatment with surgery and…”
Get full text

Genetic profiling as a clinical tool in advanced parathyroid carcinoma by Kutahyalioglu, Merve, Nguyen, Ha T., Kwatampora, Lily, Clarke, Callisia, Silva, Angelica, Ibrahim, Eiman, Waguespack, Steven G., Cabanillas, Maria E., Jimenez, Camilo, Hu, Mimi I., Sherman, Steven I., Kopetz, Scott, Broaddus, Russell, Dadu, Ramona, Wanland, Kacey, Williams, Michelle, Zafereo, Mark, Perrier, Nancy, Busaidy, Naifa L.

“…Context Parathyroid carcinoma (PC) is a rare endocrine malignancy with no approved systemic therapies for unresectable locally invasive or distant metastatic…”
Get full text

Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples by Angell, Trevor E., Wirth, Lori J., Cabanillas, Maria E., Shindo, Maisie L., Cibas, Edmund S., Babiarz, Joshua E., Hao, Yangyang, Kim, Su Yeon, Walsh, P. Sean, Huang, Jing, Kloos, Richard T., Kennedy, Giulia C., Waguespack, Steven G.

“…Introduction: The Afirma® Xpression Atlas (XA) detects gene variants and fusions in thyroid nodule FNA samples from a curated panel of 511 genes using…”
Get full text

Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: A systematic review and meta-analysis by Vander Poorten, Vincent, Goedseels, Nathan, Triantafyllou, Asterios, Sanabria, Alvaro, Clement, Paul M., Cohen, Oded, Golusinski, Pawel, Guntinas-Lichius, Orlando, Piazza, Cesare, Randolph, Gregory W., Rinaldo, Alessandra, Ronen, Ohad, Cabanillas, Maria E., Shaha, Ashok R., Teng, Yong, Tufano, Ralph P., Williams, Michelle D., Zafereo, Mark, Ferlito, Alfio

“…Background Both anaplastic thyroid carcinoma (ATC) and thyroid lymphoma (TL) clinically present as rapidly enlarging neck masses. Unfortunately, in this…”
Get full text

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer by Cabanillas, Maria E., Takahashi, Shunji

“…Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–3, fibroblast growth factor receptors 1–4, RET, KIT, and…”
Get full text

Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience by Boyce-Fappiano, David, Gjyshi, Olsi, Pezzi, Todd A, Allen, Pamela K, Solimman, Moaaz, Taku, Nicolette, Bernstein, Michael B, Cabanillas, Maria E, Amini, Behrang, Tatsui, Claudio E, Rhines, Laurence D, Wang, Xin A, Briere, Tina M, Yeboa, Debra Nana, Bishop, Andrew J, Li, Jing, Ghia, Amol J

“…Patients with metastatic thyroid cancer have prolonged survival compared to those with other primary tumors. The spine is the most common site of osseous…”
Get full text

Lenvatinib: Role in thyroid cancer and other solid tumors by Cabanillas, Maria E, Habra, Mouhammed Amir

“…Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase…”
Get full text